AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 243 min read$CLYM

One patient with kidney disease had 3 years of remission without steroids

Climb Bio (CLYM) presented Phase 2 data for budoprutug, its anti-CD19 mAb, at ASN Kidney Week. The 200 mg dose showed B-cell depletion, PLA2R Ab reduction, and immunologic remission in pMN patients. A separate case study reported 3-year steroid-free remission in an MCD patient. Additional data is expected in 2027. The drug was generally well-tolerated.

Original reporting
stocktitan.net
Published Oct 24, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLYM
Bullish
high confidence
Mentioned
$CLYM
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLYMBullishMed
01

Why it matters

The Phase 2 data provide the first immunologic readout for budoprutug in primary membranous nephropathy and a compelling remission case in minimal change disease, which could accelerate development timelines and attract partnership interest.

02

Market read

Positive early trial data for a niche renal indication can move the stock sharply; investors will watch upcoming higher‑dose cohorts and potential FDA designations.

03

What to watch

Potential manufacturing scale‑up challenges and competition from other anti‑CD19 programs could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Climb Bio (Nasdaq: CLYM) is a clinical‑stage biotech developing budoprutug, an anti‑CD19 monoclonal antibody for immune‑mediated kidney diseases.

Company-level read

Ticker impact

$CLYMBullishHigh confidence
Context

Climb Bio presented new Phase 2 data for budoprutug showing B‑cell depletion and immunologic remission in pMN and a 3‑year steroid‑free remission case in MCD.

Expected impact

likely upward pressure as market prices in the encouraging immunologic activity.

Evidence & confidence

First disclosure of Phase 2 results for a novel anti‑CD19 antibody; biotech stocks typically react strongly to early efficacy signals.

Market effects

Sector

May raise expectations for other B‑cell targeting therapies in renal and autoimmune markets.

Regional

US biotech sector could see modest lift; European peers with similar pipelines may benefit indirectly.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

Data are early‑stage and limited to small cohorts; efficacy and safety at higher doses remain unproven, so price may be overstated.

Key entities

  • Company
    Climb Bio, Inc.

    Clinical‑stage biotech developing budoprutug and other B‑cell therapies.

  • Expert
    Dr. Frank Cortazar

    Director of the New York Nephrology Vasculitis and Glomerular Center, quoted on data significance.

Read at source← All news

StoryClimb Bio presents early Phase 2 data for budoprutug in primary membranous nephropathy and minimal change disease

Related articles

OCT 24
$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

investing.com2 min
OCT 24
$CLYMMedAI 8/10

Climb Bio’s Anti-APRIL Antibody Shows ~70% Gd-IgA1 Reduction at 12 Weeks

Climb Bio (CLYM) and Beijing Mabworks reported Phase 1 data showing their anti-APRIL antibody reduced Gd-IgA1 by ~70% and IgA by ~60% at 12 weeks in healthy volunteers. The trials involved 88 participants across Australia and China. The antibody was well-tolerated, with no serious adverse events. The company plans to initiate a Phase 3 trial in 2027, pending regulatory feedback.

minichart.com.sg2 min
OCT 23
$CLYMMedAI 8/10

Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

tradingview.com1 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

SEC EDGAR 8-K2 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.

markets.businessinsider.com3 min